An 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the Acute Treatment of DSM-IV Generalized Anxiety Disorder in Outpatients.
Active, not recruiting
- Conditions
- Generalized anxiety disorder.MedDRA version: 6.1Level: PTClassification code 10002855
- Registration Number
- EUCTR2004-001500-13-IT
- Lead Sponsor
- PFIZER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pregabalin's efficacy in treating generalized anxiety disorder compared to venlafaxine XR?
How does the flexible dosing of pregabalin and venlafaxine XR in EUCTR2004-001500-13-IT compare to standard-of-care treatment protocols for GAD?
Which biomarkers are associated with differential response to pregabalin versus venlafaxine XR in patients with generalized anxiety disorder?
What are the adverse event profiles and management strategies for pregabalin and venlafaxine XR in acute GAD treatment?
How do pregabalin and venlafaxine XR compare to other SNRIs or GABA analogs in the treatment of generalized anxiety disorder?